November 23, 2021 10:37 AM ESTUpdated 10:47 AM

$107B in 2+ years? Pfizer’s Covid-19 vaccine may redefine ‘megablockbuster’ by 2022 — analyst

Amber Tong

If both its BioNTech-partnered Covid-19 vaccine and in-house antiviral live up to their full promises, Pfizer may be sitting on a $100 billion goldmine in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

$107B in 2+ years? Pfizer’s Covid-19 vaccine may redefine ‘megablockbuster’ by 2022 — analyst

Amber Tong

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

$107B in 2+ years? Pfiz­er’s Covid-19 vac­cine may re­de­fine ‘megablock­buster’ by 2022 — an­a­lyst

Amber Tong

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

$107B in 2+ years? Pfizer’s Covid-19 vaccine may redefine ‘megablockbuster’ by 2022 — analyst

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?